WuXi PharmaTech, Combined with U.S. Firm, Sets Sights on Global Market
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Fresh after acquiring U.S. biologics firm AppTec Laboratory Services, WuXi PharmaTech is pushing to rapidly broaden its scope of operations and widen its customer base worldwide, according to WuXi CEO Li Ge
You may also be interested in...
Following Massive Loss Last Year, Chinese CRO WuXi PharmaTech Posts Remarkable Rebound During First Quarter Of 2009
BEIJING - After reporting a devastating $64 million loss for 2008, the leadership of WuXi PharmaTech said that the company had moved back into the black in the first quarter of this year with net income of more than $11 million
Following Massive Loss Last Year, Chinese CRO WuXi PharmaTech Posts Remarkable Rebound During First Quarter Of 2009
BEIJING - After reporting a devastating $64 million loss for 2008, the leadership of WuXi PharmaTech said that the company had moved back into the black in the first quarter of this year with net income of more than $11 million
Hit By U.S. Economic Tremors, Collapse In Biologics Business, WuXi PharmaTech Posts Massive Loss For 2008, American Unit AppTec Deeply Devalued
BEIJING - Battered in succession by the unstable U.S. economy, faltering biologics customers and mounting losses by American subsidiary AppTec Laboratory Services, WuXi PharmTech reported a net loss of more than $60 million for 2008